Cel­gene co-founder Sol Bar­er bags a Johns Hop­kins im­muno-on­col­o­gy spin­out in buy­out

A few weeks ago, Johns Hop­kins Pro­fes­sor Jonathan Sch­neck pub­lished new re­search show­ing how the bio­mimet­ic nano beads he had cre­at­ed in the lab could work with a check­point in­hibitor in fight­ing can­cer. These beads were de­signed to act as anti­gen pre­sent­ing cells aimed at whip­ping up a full scale killer T cell at­tack on can­cer as the check­point stripped the can­cer cells of their built-in de­fense sys­tem.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.